The molecular profiling of another 6 patients (with bladder or lung cancer, endometrial sarcoma or triple-negative breast cancer) with hyperprogression in response to anti-PD-1 and anti-CTLA-4 therapy was associated with MDM2/MDM4 amplifications (all cases) and epidermal growth factor receptor (EGFR) mutations (2 patients) [35]. The gene discussed is PDCD1; the disease is triple-negative breast carcinoma.